AAM Speaks Out Against Build Back Better Bill

US Pricing Policy Could Unfairly Penalize Generics And Biosimilars Manufacturers

 
• By Chloe Kent
  
Joe Biden Build Back Better
Biden's Build Back Better Bill Has Been Criticized By The AAM • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Policy & Regulation

More from Generics Bulletin